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Open acAbstract Background: EMD 521873 (Selectikine), an immunocytokine comprising a DNA-
targeting antibody, aimed at tumour necrosis, fused with a genetically modiﬁed interleukin-
2 (IL-2) moiety, was investigated in this ﬁrst-in-human phase I study.
Methods: Patients had metastatic or locally advanced solid tumours failing previous standard
therapy. Selectikine was administered as a 1-hour intravenous infusion on 3 consecutive days,
every 3 weeks. A subgroup of patients also received 300 mg/m2 cyclophosphamide on day 1 of
each cycle. Escalating doses of Selectikine were investigated with the primary objective of
determining the maximum tolerated dose (MTD).
Results: Thirty-nine patients were treated with Selectikine alone at dose levels from 0.075 to
0.9 mg/kg, and nine were treated at doses of 0.45 and 0.6 mg/kg in combination with cyclo-
phosphamide. A dose-dependent linear increase of peak serum concentrations and area under
curve was found. The dose-limiting toxicity was grade 3 skin rash at the 0.9 mg/kg dose-level;
the MTD was 0.6 mg/kg. Rash and ﬂu-like symptoms were the most frequent side-effects. No15
versity of Lausanne Hospitals (CHUV), 46, rue du Bugnon, Lausanne 1011, Switzerland. Tel.: +41 21 314
ch (R. Stupp).
rankfurt, Germany.
uticals Ltd, Allschwil, Switzerland.
this manuscript.
nsins, Switzerland, an aﬃliate of Merck KGaA, Darmstadt, Germany.
cess under CC BY-NC-ND license. 
36 S. Gillessen et al. / European Journal of Cancer 49 (2013) 35–44severe cardiovascular side-effects (hypotension or vascular leak) were observed. At all dose-
levels, transient increases in total lymphocyte, eosinophil and monocyte counts were recorded.
No objective tumour responses, but long periods of disease stabilisation were observed. Tran-
sient and non-neutralising Selectikine antibodies were detected in 69% of patients.
Conclusions: The MTD of Selectikine with or without cyclophosphamide administered under
this schedule was 0.6 mg/kg. The recommended phase II dose was 0.45–0.6 mg/kg. Selectikine
had a favourable safety proﬁle and induced biological effects typical for IL-2.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Immunocytokines comprise a monoclonal antibody
fused to a cytokine. Targeting tumour antigens via the
antibody moiety facilitates cytokine enrichment in the
local tumour microenvironment, achieving the concen-
trations required to induce an eﬀective immune
response.1 In murine cancer models, interleukin-2 (IL-
2)-containing immunocytokines demonstrated superior
dose-dependent antitumour activity compared with
equimolar doses of the free cytokine and antibody.2–4
IL-2 demonstrates antitumour activity,5–7 and was
the ﬁrst cytokine to be fused to tumour-targeting anti-
bodies, but similar to free recombinant IL-2, severe
hypotension and vascular leak syndrome remained
dose-limiting when immunocytokines were tested in
patients with advanced solid tumours.8–11 EMD
521873 or NHS-IL2LT (Selectikine, Merck KGaA,
Darmstadt, Germany) is a novel immunocytokine com-
prising genetically modiﬁed IL-2 with decreased vascu-
lar toxicity fused with a DNA-targeting antibody
moiety, NHS76.
NHS76, a fully human de-immunised monoclonal
antibody,12 binds free DNA fragments without require-
ments for speciﬁc nucleotide sequences or recognised
secondary structures (Merck KGaA data on ﬁle).
DNA is often released from dying tumour cells, either
spontaneously, or during their exposure to radiation
or chemotherapy.13–16 Systemic or intra-tumoural
administration of TNT1, (iodine131 radio-labelled pre-
cursor of NHS76) successfully targeted diﬀerent tumour
types.17–20
Selectikine acts predominantly on activated T-cells
via the high-aﬃnity IL-2 receptor, and shows minimal
activity for the intermediate-aﬃnity receptor, a sus-
pected mediator of vascular toxicity mainly expressed
by NK cells.21 Genetic modiﬁcation of the fusion junc-
tion (M1) of Selectikine has increased its serum half-
life.22
In preclinical studies, CD8-dependent Selectikine
antitumour activity was shown in murine tumour mod-
els.21 Intermittent dosing every three weeks in cynomol-
gus monkeys was well tolerated, without the induction
of cardiovascular side-eﬀects.18 Mild to moderate side-
eﬀects were observed including typical IL-2-target organ
toxicity and a transient increase in lymphocyte subpop-ulations.21 Selectikine generally demonstrated a better
safety proﬁle than other immunocytokines containing
unmodiﬁed IL-2 (Merck KGaA, data on ﬁle).
This ﬁrst-in-man phase I clinical trial investigated the
safety and tolerability of Selectikine in patients with
refractory, advanced solid tumours. IL-2 treatment
induces an increase in regulatory T-cells, which express
the high-aﬃnity IL-2 receptor and can also be activated
by Selectikine. Low-dose cyclophosphamide might
potentiate the antitumour activity of immunotherapies
via depletion of regulatory T-cells,23–26 and was associ-
ated with increased lymphokine-activated killer cells in
IL-2 treated melanoma patients.27 Combining low-dose
cyclophosphamide with Selectikine was explored in this
trial to investigate if the anticipated eﬀect of Selectikine
on regulatory T-cells could be limited.
2. Materials and methods
2.1. Study design
This open-label, multicentre phase I study aimed to
determine the Selectikine maximally tolerated dose
(MTD) administered alone (group 1) or with low-dose
cyclophosphamide (group 2). Secondary objectives were
to evaluate pharmacokinetics (PK), immunogenicity,
biological and clinical response, progression-free sur-
vival (PFS) and overall survival (OS). The regimen
was selected based on preclinical data and prior clinical
experience with other immunocytokines containing
unmodiﬁed IL-2.8–10,21,28
The study was performed with local ethics committee
and regulatory authority approval and in accordance
with the declaration of Helsinki and the International
Conference on Harmonization.
2.2. Main patient eligibility criteria
All patients gave written informed consent. Eligible
patients were P18 years, with Eastern Cooperative
Oncology Group performance status of 61, adequate
organ function, histologically/cytologically proven solid
tumours or B-cell non-Hodgkin’s lymphoma after fail-
ure of standard therapy. Patients requiring treatment
with immunosuppressive agents, or having autoimmune
disease, inﬂammatory bowel disease, chronic viral infec-
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were ineligible.
2.3. Treatment
Selectikine, (intravenous [iv] infusion over 1 h) was
administered on days 1–3 of a 21-day cycle. Group 2
patients received 300 mg/m2 cyclophosphamide (iv infu-
sion over 1 h), 1 day before the ﬁrst Selectikine dose in
each cycle. Treatment continued until tumour progres-
sion or the occurrence of intolerable side-eﬀects. Pre-
and co-medication included a non-steroidal anti-inﬂam-
matory drug to alleviate ﬂu-like symptoms.
2.4. Dose escalation
The starting dose of 0.075 mg/kg Selectikine was cho-
sen after preclinical evaluation (Merck KGaA data on
ﬁle). Rapid dose-escalation was planned if no relevant
Pgrade 2 toxicity was observed with two single-patient
cohorts. Otherwise, three-patient cohorts were treated
per dose level, with expansion to six-patient cohorts in
the presence of dose limiting toxicity (DLT). No intra-
patient dose-escalation was allowed. Dose-escalation
occurred if 0/3 or 61/6 patients experienced DLT,
deﬁned as any grade P3 treatment-related adverse
events (AEs) occurring in cycle 1. Grade 3 fever and
chills lasting <6 h, allergic reactions, grade 3 rash
improving to grade 2 in <24 h, grade 3 nausea and vom-
iting improving with antiemetic treatment, and speciﬁed
laboratory abnormalities were not considered DLTs.
Patients receiving at least one Selectikine dose were
evaluable for DLTs. Patients not experiencing DLTs
should have received the full scheduled doses in cycle 1
to be included in the DLT analysis, patients discontinu-
ing early for reasons other than toxicity were replaced.
The MTD was the highest dose in cycle 1 in which
there were no DLTs/3 patients or 61 DLT/6 patients.
Following MTD determination, additional patients
were enrolled (group 1a) at dose levels below the
MTD to obtain further information on changes in bio-
logical parameters.
2.5. Clinical assessments
Assessments were performed on days 1, 3, 4 and 8,
and at the end of study visit 28 days after the last
dose Selectikine. Vital signs were recorded at the start
of infusion, every 15 min until the end of the infusion
(EOI), then every 30 min until 2 h after EOI and then
hourly until 6 h after EOI. AEs were graded by the
National Cancer Institute (NCI) common criteria for
AEs (version 3.0). Tumour response was assessed
every 6 weeks according to RECIST29 and patients
were followed until death or for P1 year after study
closure.2.6. Pharmacokinetic and pharmacodynamic analysis
Serum Selectikine was analysed by an enzyme-linked
immunosorbent assay (ELISA, Supplemental Material).
PK analysis was performed using Kineticae (version
4.4.1 2002, Innaphase PA, USA). Patient Selectikine
PK parameters were determined on day 1 of cycles 1
and 3 by non-compartmental analysis. Single-dose
parameters included: maximum serum concentration
(Cmax), time to reach maximum serum concentration
(tmax), area under the curve (AUC) from time zero to
time of last concentration above lower limit of
quantiﬁcation (AUC0-t), AUC from time zero to inﬁnity
(AUC0-1), and terminal half life (t1/2). Accumulation
was assessed by comparing the day 1 values for
AUC0–t and Cmax between cycles 1 and 3 and the EOI
and pre-infusion concentrations on days 1 and 2 of
cycles 1–3. Selectikine dose proportionality was assessed
by plotting the dose-dependent parameters Cmax and
AUC0-t as a function of various absolute dose levels
administered on day 1 of cycle 1.
2.7. Immunogenicity
Serum Selectikine antibodies were detected using a
bridging ELISA (Supplemental Material).
2.8. Statistical methods
Descriptive statistics were used for baseline character-
istics, safety assessments, PK and immunogenicity vari-
ables. Survival analyses were performed by the Kaplan–
Meier method. Counts of leukocyte subsets were com-
pared between days 1 and 8 of the ﬁrst two cycles using
repeated measurements mixed model analysis of vari-
ance (ANOVA). Full statistical analyses are described
in the Supplemental Material.
3. Results
3.1. Patient characteristics and MTD determination
Between December 2006 and May 2009, 48 patients
were enrolled: 39 were treated with Selectikine alone
(group 1) and nine with Selectikine plus cyclophospha-
mide (group 2) (Table 1). Thirty-seven patients were
evaluable for DLT and 42 for eﬃcacy.
Selectikine dose levels and DLTs are summarised in
Table 2. In group 1, two potential DLTs were observed
at 0.3 mg/kg, the study was continued at the previous
dose level (0.15 mg/kg) with no further DLTs. The pro-
tocol was subsequently amended to exclude asymptom-
atic intermittent laboratory changes as DLTs, and doses
were escalated by 50% instead of 100% dose-increments
up to 0.9 mg/kg. Four DLTs were reported: one grade 3
dyspnoea (0.3 mg/kg) and three grade 3 skin rash (one
Table 1
Patient and disease characteristics at baseline.
Characteristic Group 1 (n = 39) Group 2 (n = 9)
Median age, years (range) 60 (24–76) 52 (31–78)
Sex, n (%)
Male 22 (56) 3 (33)
Female 17 (44) 6 (67)
ECOG PS, n (%)
0 29 (74) 7 (78)
1 10 (26) 2 (22)
Tumour type, n (%)
Colorectal carcinoma 15 (39) 1 (11.1)
Ovarian carcinoma 6 (15) 1 (11.1)
Prostate carcinoma 3 (8) 0
Renal cell carcinoma 4 (10) 0
Skin carcinoma 2 (5) 2 (22.2)
Other 9a (18) 5b (55.5)
Time from metastatic/recurrence diagnosis to study entry, Median, (range in years) 2.39 (0.1–6.2) 2.05 (1.3–8.7)
Previous therapyc
Surgery 35 (90) 7 (78)
Chemotherapy 36 (92) 9 (100)
Radiotherapy 16 (41) 6 (67)
Monoclonal antibody 15 (39) 2 (22)
Hormonal 6 (15) 1 (11)
Immunotherapy 7 (18) 3 (33)
Other 14 (36) 1 (11)
ECOG PS, Eastern Cooperative Oncology Group performance status.
a One of each: adrenal gland carcinoma; breast carcinoma; hypopharyngeal carcinoma; non small cell lung carcinoma; small cell lung carcinoma;
osteosarcoma; pleural mesothelioma; urothelial carcinoma and endometrial carcinoma.
b One of each: parotid gland carcinoma; synovial sarcoma; tongue carcinoma; thymic carcinoma; nasopharyngeal carcinoma.
c Excluding palliative radiotherapy and surgery.
Table 2
Selectikine dosing and DLTs.
Dose level
(mg/kg)
Number of patients DLT and grade 3 toxicitya
Group 1
(n = 28)
Group 2
(n = 9)
Group 1a
(n = 11)
0.075 1 0 5 None
0.15 6 0 0 One patient with grade 3 lymphopenia and PTT increase, not clinically relevant (no DLT
recorded as per amended protocol)
0.225b 3 0 3 None
0.3 6 0 0 1 DLT; grade 3 dyspnoea without evidence of vascular leak (no oedema or inﬁltrates on high
resolution CT scan), ﬁnally assessed as related to tumour progression
One patient with grade 3 increase in lipase, not clinically relevant (no DLT recorded as per
amended protocol)
0.45b 3 3 3 None
0.6 6 6 0 1 DLT; grade 3 rash in group 1 and 1 DLT; grade 3 rash in group 2
0.9 3 0 0 2 DLTs; grade 3 rash
DLT, dose limiting toxicity; PTT, partial thromboplastin time; CT computed tomography.
a Grade 3 toxicities after cycle 1 in group 1a only.
b These doses were included following suspected DLTs at the 0.3 mg/kg dose. Following a protocol amendment to exclude asymptomatic
intermittent laboratory changes from DLT, Selectikine dosing was returned to the previous dose level and dose escalation restarted by 50% instead
of 100% dose increments.
38 S. Gillessen et al. / European Journal of Cancer 49 (2013) 35–44at 0.6 mg/kg and two at 0.9 mg/kg). The Selectikine
MTD was determined as 0.6 mg/kg.
Eleven patients (group 1a) were subsequently
enrolled and treated with Selectikine at 0.075, 0.225
and 0.45 mg/kg in a sequential order.Nine patients were treated in group 2 (Selectikine
0.45 mg/kg and 0.6 mg/kg), one experienced a DLT
(grade 3 skin rash at 0.6 mg/kg).
The median number of cycles per patient was 2 (range
1–10). The majority of patients (n = 20) received 2
S. Gillessen et al. / European Journal of Cancer 49 (2013) 35–44 39treatment cycles. Treatment was discontinued in 37
patients (77.1%) due to progressive disease (PD), and
in 11 (22.9%) due to toxicity.3.2. Safety
Dose-dependent skin rash was the most frequently
reported AE (48%) and generally improved rapidly with
the use of topical steroids and antihistamine agents.
Fever (640 C) occurred in 40% of patients at doses
P0.225 mg/kg (Table 3). Other AEs appeared to be
independent of dose and included lymphopenia (44%),
dry skin (40%) and mild (grade 1) hypotension (31%).
Fourteen patients discontinued treatment due to
AEs: grade 2 leukocytoclastic vasculitis (n = 1), grade
2 autoimmune thyroiditis (n = 1), dyspnoea (n = 1),
transaminase increase (n = 1), grade 3 skin rash
(n = 7), exacerbation of psoriasis (n = 1) and grade 2
and 3 angioedema (n = 2). The main reason for study
withdrawal was PD reported in three of these patients.
In both patient groups transient changes in lympho-
cyte counts were found, which decreased on day 3,Table 3
Treatment-related adverse events (AEs) occurring in more than 20% of pa
Adverse event Dose levels (mg/kg)
Group 1, n
0.075
(n = 6)
0.15
(n = 6)
0.225
(n = 6)
0.3
(n = 6)
0.45
(n = 6)
Rash
Any grade 1 3 3 3 3
Grade 1/2 1 3 3 3 2
Grade 3/4 0 0 0 0 1
Erythema
Any grade 2 0 2 1 1
Grade 1/2 2 0 2 1 1
Grade 3/4 0 0 0 0 0
Dry skin
Any grade 4 2 1 2 1
Grade 1/2 4 2 1 2 1
Grade 3/4 0 0 0 0 0
Fever
Any grade 0 0 2 2 4
Grade 1/2 0 0 2 2 4
Grade 3/4 0 0 0 0 0
Lymphopenia
Any grade 1 3 4 3 1
Grade 1/2 1 0 3 1 1
Grade 3/4 0 3 1 2 0
Hypotension
Any grade 2 2 2 2 2
Grade 1 2 2 2 2 2
Grade 2/3/4 0 0 0 0 0
Asthenia
Any grade 0 2 2 1 1
Grade 1/2 0 2 2 1 1
Grade 3/4 0 0 0 0 0returning to normal and increasing signiﬁcantly above
baseline on day 8 (Supplemental Material).3.3. Pharmacokinetics
PK analysis was performed on all 48 patients during
cycle 1 and on nine patients during cycle 3. Post-dose con-
centrations were above the lower limit of quantiﬁcation
(LLOQ) for all dose levels. Peak serum Selectikine con-
centrations were reached at the EOI, thereafter declining
continuously without a noticeable distribution phase.
At the end of day 1, quantiﬁable concentrations were
detectable in all 24-hour samples (except the 0.075 mg/
kg dose; Fig. 1). Descriptive statistics are shown in
Table 4. Individual Cmax and AUC values (group 1,
day 1, of cycle 1) analysed as a function of absolute
administered dose (mg) indicated a proportional
increase in Cmax, AUC0-t and AUC0-1 up to a threshold
of approximately 40 mg, which corresponded to a dose-
range between 0.45 and 0.6 mg/kg (Figs 2A–C).
Analysis of within-cycle accumulation showed that
pre-dose concentrations did not increase from daystients by diﬀerent dose levels in groups 1 and 2.
Group 2, n
0.6
(n = 6)
0.9
(n = 3)
0.45
(n = 3)
0.6
(n = 6)
Total, n (%) all
doses (n = 48)
3 2 2 3 23 (47.9)
2 0 2 2 18 (37.5)
1 2 0 1 5 (10.4)
4 0 0 3 13 (27)
4 0 0 3 13 (27)
0 0 0 0 0
3 1 2 3 19 (39.6)
3 1 2 3 19 (39.6)
0 0 0 0 0
3 3 2 3 19 (39.6)
3 3 2 3 19 (39.6)
0 0 0 0 0
2 0 2 5 21 (43.8)
1 0 1 2 10 (20.8)
1 0 1 3 11 (22.9)
2 0 1 2 15 (31.2)
2 0 1 2 15 (31.2)
0 0 0 0 0
1 2 1 1 11 (22.9)
1 2 1 1 11 (22.9)
0 0 0 0 0
Fig. 1. Mean (standard deviation) concentration–time proﬁle for Selectikine after the ﬁrst infusion (day 1) of cycle 1.
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across all dose-levels (1.15, 1.14 and 1.04 for cycles 1, 2 and
3, respectively). The corresponding Cmax(day3)/Cmax(day2)
ratios did not reveal signiﬁcant day-to-day accumula-
tion (0.97, 1.14 and 1.03 for cycles 1, 2 and 3, respec-
tively). Predose concentrations on day 1 of cycle 3
were mainly below the LLOQ, suggesting no measurable
accumulation from the previous cycle. Nevertheless a
1.3–1.9 fold increase for Cmax and a 1.8–2.6 increase
for AUC0-t were observed in cycle 3, when compared
to cycle 1. The t1/2 ranged between 7.8 and 11 h in cycle
1 and between 9.5 and 18 h in cycle 3 in both groups.
Pre-treatment with cyclophosphamide may result in a
slight decrease in exposure to Selectikine, but this was
not statistically signiﬁcant.
3.4. Immunogenicity
Serum Selectikine antibodies were detected in 33/48
patients (69%), with peaks occurring on day 8 of cycle
1 in the majority. A decline in antibody detection with
subsequent administrations suggested a transient
immune response against Selectikine. Antibodies did
not appear to be neutralising as they inﬂuenced neither
the PK nor the biological activity of Selectikine.
Increases in total lymphocytes, CD4+, CD8+ and NK
cells in cycles 1 and 2 were not reduced by the presence
of Selectikine antibodies (data not shown).
3.5. Antitumour activity
No tumour responses were recorded, however SD for
>6 weeks was noted in 12/48 (25%) patients. Median
survival time was 9.6 months (95% CI 5.6–16.4) in group
1 and 7.0 months (95% CI 4.3–23.2) in group 2.
Selectikine treatment was associated with a potential
clinical beneﬁt in four patients, one patient with refrac-
tory recurrent small cell lung cancer (stable for >10months), two patients with colorectal cancer and one
patient with ovarian cancer (Supplemental Material).
4. Discussion
In this ﬁrst-in-human phase I study, Selectikine treat-
ment was associated with typical IL-2-like biological
eﬀects including lymphopenia followed by lymphocytosis
and eosinophilia at all dose levels, while IL-2 related clin-
ical AEs were mainly mild to moderate. DLT was skin
rash, which responded well to topical corticosteroids.
In previous studies with intermediate to high IL-2
doses, or with other IL-2-based immmunocytokines,
vascular leak syndrome and hypotension were common
side-eﬀects, thought to be due to activation of the inter-
mediate-aﬃnity IL-2 receptor and direct activation of
endothelial cells.8–10 In contrast, Selectikine induced
only mild hypotension and no vascular leak syndrome
demonstrating improved cardiovascular tolerability of
the modiﬁed and more selective IL-2 moiety.
Following administration, Selectikine PK appeared
to be linear. The increased exposure and prolonged
Selectikine half-life in cycle 3 was surprising; predose
levels measured at day 1 were below LLOQ and no iden-
tiﬁable changes in physiological factors, which might
have impacted on clearance rate or volume of distribu-
tion were found. While the reported dose–exposure rela-
tionship for Selectikine was similar to that observed for
other structurally related fusion proteins, the Selectikine
half-life was notably longer than that reported for other
IL-2 immunocytokines or unmodiﬁed recombinant IL-
2.8,9,28 This comparatively longer half-life can be attrib-
uted to the lysine to alanine amino acid substitution in
the junction sequence between antibody and IL-2 com-
ponent. This eﬀect is assumed to be independent of
binding to either Fcc receptors or the Fc protection
receptor, but was associated with changes in susceptibil-
ity to intracellular proteases.22
Table 4
Main pharmacokinetic (PK) parameters of serum Selectikine obtained on day1 following ﬁrst infusion cycle 1 and cycle 3.a
Parametera Treatment groups/cycle/dose (mg/kg)
Group 1/cycle 1 Group 1/ cycle 3 Group 2/cycle 1 Group
2/cycle 3
0.075
(n = 6)
0.15
(n = 6)
0.225
(n = 6)
0.3
(n = 6)
0.45
(n = 6)
0.6
(n = 6)
0.9
(n = 6)
0.075
(n = 3)
0.15
(n = 3)
0.3
(n = 1)
0.6
(n = 1)
0.45
(n = 3)
0.6
(n = 6)
0.6
(n = 1)
Dose, mg
Mean 5.2 12.4 16.4 23.4 30.9 38.2 73.2 5.6 10.3 30 27.6 28.4 43.3 35.0
Co-eﬃcient of
variation (CV) %
33.7 14.3 20.9 15.5 24.2 21.1 3.9 34.9 19.3 9.3 15.6
Range 2.9–7.6 9.8–14.3 13.0–21.4 19.7–30.0 20.0–39.6 27.6–49.0 70.0–75.6 3.6–7.5 8.6–12.5 26.1–31.3 33.0–50.0
Cmax, lg/mL
Mean 1.1 2.7 3.7 4.7 8.2 7.8 10.5 1.8 3.1 8.6 11.4 6.2 7.4 7.6
CV% 46.0 26.2 18.0 21.7 34.7 30.5 18.5 32.5 17.8 21.3 42.1
Range 0.5–1.8 2.0–4.2 2.9–4.6 3.5–6.3 6.0–12.7 5.4–10.7 8.5–11.8 1.5–2.6 2.6–3.6 5.2–7.8 4.3–12.1
tmax, hrs
Median 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 2.0 1.0 1.0 1.0
Range 1.0–2.0 1.0–1.1 1.0–1.4 1.0–2.0 1.0–1.1 1.0–2.0 0.5–1.0 1.0–1.1 1.0–1.1 1.0–1.0 1.0–1.0
AUC0-t lg/mL
h
Mean 7.9 24.0 30.1 39.0 55.0 57.8 83.3 15.5 40.8 110.9 153.4 44.8 46.6 84.1
CV% 67.9 22.9 9.2 17.1 28.5 24.8 29.1 92.0 28.9 20.4 31.8
Range 2.9–5.9 16.9–32.2 26.6–33.6 30.1–47.1 33.5–73.9 39.0–69.9 63.8–112.5 6.5–29.9 29.5–50.0 37.0–55.3 33.6–78.4
AUC0-1 lg/mL
h
Mean 12.0 29.0 35.2 47.7 68.6 70.0 106.3 21.6 60.3 171.4 249.5 52.5 56.2 115.9
CV% 52.3 25.1 11.5 16.2 33.1 21.2 27.2 104 44.4 20.3 35.2
Range 5.0–19.8 18.9–39.7 29.8–39.5 36.1–55.7 40.3–105.1 47.7–81.7 89.4–144.5 8.4–44.5 37.2–82.0 43.8–65.2 39.4–94.4
t1/2, hrs
Mean 7.8 9.3 8.3 9.9 10.0 9.5 11.1 9.5 14.0 15.5 17.7 8.7 10.1 12.5
CV% 31.2 19.0 12.6 12.7 29.2 17.3 26.5 72.7 27.9 4.8 19.8
Range 5.2–11.9 7.2–12.3 6.6–9.7 8.6–11.6 7.5–15.5 8.0–12.7 8.6–14.4 4.5–14.5 10.2–16.9 8.4–9.2 8.4–14.5
AUC0-t, area under the serum concentration–time curve from time zero to the time of the last concentration above the lower limit of quantiﬁcation; AUC0-1, area under the serum concentration–time
curve from time zero to inﬁnity; Cmax, maximum observed serum concentration; CV, co-eﬃcient of variation; t1/2, terminal half life; tmax, time to reach maximum serum concentration.
a Means are geometric means, apart from means for dose.
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concentration; AUC0-t, area under the serum concentration–time curve from time zero to the time of the last concentration above the lower limit of
quantiﬁcation; AUC0-1, area under the serum concentration–time curve from time zero to inﬁnity.
42 S. Gillessen et al. / European Journal of Cancer 49 (2013) 35–44A transient clinically irrelevant immunogenic eﬀect
was observed in the majority of patients (69%). Anti-
body responses were also observed after treatment with
other IL-2-immunocytokines.8–10 Interestingly, preli-
minary immunogenicity data from a phase I trial with
L19-IL-2, consisting of the recombinant human anti-body fragment L19 (highly speciﬁc for the extra domain
B of ﬁbronectin), fused with unmodiﬁed human IL-2
indicate a very low immunogenic potential.9
Antitumour activity was reported in this heteroge-
neous and heavily pretreated patient population as pro-
longed disease stabilisation and a transient drop in
S. Gillessen et al. / European Journal of Cancer 49 (2013) 35–44 43tumour markers. Combination or intercalation of
immunocytokine treatment with chemotherapy or radi-
ation may facilitate the generation of an eﬀective antitu-
mour immune response by increased tumour antigen
release, and activation of dendritic cells and tumour
antigen speciﬁc T-cells.30 Also IL-2 containing immuno-
cytokines may be clinically more eﬀective if administered
in patients with less tumour burden or non-bulky
tumour disease. In a phase II study in children with
refractory neuroblastoma, whereas no responses were
observed in children with bulky metastatic disease, com-
plete responses occurred in 5/23 (21.7%) children with
low disease burden.31
The data indicate that low-dose cyclophosphamide
can be safely combined with Selectikine without the
need for dose reductions of the immunocytokine. While
the PK was not appreciably modiﬁed, the number of
patients treated with cyclophosphamide is too low to
draw reliable conclusions. Detailed analyses of a poten-
tial eﬀect on immune responses are ongoing.
In conclusion, compared with historical data report-
ing IL-2 treatment, improved cardiovascular tolerance
and an overall favourable safety proﬁle were demon-
strated for Selectikine, a novel immunocytokine with
selective IL-2 activity targeting free DNA. DLT was
skin rash and a dose of 0.45–0.6 mg/kg was recom-
mended for further phase II evaluation. Further trials
of this compound in combination with standard chemo-
therapy and radiotherapy or in patients with limited
tumour burden are warranted.Conﬂict of interest statement
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